Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference

AUSTIN, Texas--(BUSINESS WIRE)--Nov. 26, 2019-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four Seasons Hotel in Boston. Taneli Jouhikainen, Savara’s President and Chief Operating Officer, and Badrul Chowdhury, Savara’s Chief Medical Officer, will participate in a fireside chat at the conference.

Interested parties can access a live audio webcast of the fireside chat on the Investors page of the Savara website at An archived presentation will be available on Savara's website for 90 days following the event.

About Savara

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at (Twitter: @SavaraPharma, LinkedIn:

Source: Savara Inc.

Savara Inc. IR & PR
Anne Erickson (
(512) 851-1366